

September 5, 2017



# **Aptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference**

SAN DIEGO and TORONTO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the 19<sup>th</sup> Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainright & Co., LLC., on Monday, September 11, 2017 at 9:35 a.m. ET at the Lotte New York Palace Hotel in New York, NY.

Dr. Rice will provide a corporate overview of the Company's recent activities and strategic direction.

Time: 9:35 a.m. ET  
Date: Monday, September 11, 2017  
Location: Lotte New York Palace Hotel, New York, NY

A live webcast of the Aptose presentation will be accessible by visiting:

<http://wsj.com/webcast/rrshq27/apto>

The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at [www.aptose.com](http://www.aptose.com)

## **About Aptose**

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit [www.aptose.com](http://www.aptose.com).

For further information, please contact:

Aptose Biosciences  
Greg Chow, CFO  
647-479-9828  
[gchow@aptose.com](mailto:gchow@aptose.com)

SMP Communications  
Susan Pietropaolo  
201-923-2049  
susan@smpcommunications.com



Source: Aptose Biosciences Inc.